Page last updated: 2024-09-02

3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and Chronic Illness

3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide has been researched along with Chronic Illness in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gray, JA; Gray, NS; Kerwin, RW; Pilowsky, LS1
Holzmann, T; Hör, G; Maul, FD; Pflug, B; Schreiner, M; Volk, S; Weppner, M1

Other Studies

2 other study(ies) available for 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and Chronic Illness

ArticleYear
Latent inhibition in drug naive schizophrenics: relationship to duration of illness and dopamine D2 binding using SPET.
    Schizophrenia research, 1995, Volume: 17, Issue:1

    Topics: Adolescent; Adult; Attention; Basal Ganglia; Benzamides; Chronic Disease; Contrast Media; Corpus Striatum; Female; Humans; Male; Neural Inhibition; Neuropsychological Tests; Pyrrolidines; Receptors, Dopamine D2; Schizophrenia; Schizophrenic Psychology; Tomography, Emission-Computed, Single-Photon

1995
Dopamine D2 receptor occupancy measured by single photon emission computed tomography with 123I-Iodobenzamide in chronic schizophrenia.
    Psychiatry research, 1994, Volume: 55, Issue:2

    Topics: Adult; Antipsychotic Agents; Basal Ganglia; Benzamides; Chronic Disease; Contrast Media; Dopamine Antagonists; Female; Frontal Lobe; Humans; Iodine Radioisotopes; Male; Middle Aged; Prognosis; Psychiatric Status Rating Scales; Pyrrolidines; Receptors, Dopamine D2; Schizophrenia; Tomography, Emission-Computed, Single-Photon

1994